Jianfeng Group Lin2016 -028 (Announcement on Acceptance Notice of Drug Clinical Trial Application of Subsidiary Company)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2016-028
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Acceptance Notice of Subsidiary Drug Clinical Trial Application
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
1. Summary
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a controlling subsidiary of the Company, received the Notice of Acceptance of Drug Registration Application (Acceptance No.: CXHL1600201 Zhejiang) and (Acceptance No.: CXHL1600202 Zhejiang) issued by Zhejiang Food and Drug Administration. The clinical research application of deoxypodophyllotoxin for injection (acceptance number: CXHL1600202 Zhejiang) and its bulk drug (acceptance number: CXHL1600201 Zhejiang) (hereinafter collectively referred to as "DPT") developed by Jianfeng Pharmaceutical and China Pharmaceutical University has been accepted by Zhejiang Food and Drug Administration.
2. drug basic information content
(I) deoxypodophyllotoxin
drug name: deoxypodophyllotoxin
dosage form: non-preparation: bulk drug
packing specification: 2Kg
per bag application item: chemical drug: class 1
Application Stage: Clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd., China Pharmaceutical University
Application Acceptance Number: CXHL1600201 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
(II) Deoxypodophyllotoxin for Injection
Drug Name: Deoxypodophyllotoxin for Injection
Dosage Form: Preparation: Chinese Pharmacopoeia Dosage Form Injection
Specification: 100mg Package Specification: 1 bottle per box
Application Item: Chemical Drug: 1 Class
Application Stage: clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd. and China Pharmaceutical University
Application Acceptance Number: CXHL1600202 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
3. Drug Research and Development and Registration
DPT Project is a new anti-tumor drug developed by Jianfeng Pharmaceutical in cooperation with China Pharmaceutical University in March 112. Domestic and foreign listed alkaloids of similar drugs include: paclitaxel, vinorelbine. DPT indication/ function indication is tentatively designated as first-line and second-line treatment of lung cancer, breast cancer and gastric cancer; Especially for the treatment of the above tumors resistant to paclitaxel and vinorelbine.
DPT is currently in the stage of applying for clinical trial approval. After the clinical application of is accepted, the clinical research work can only be carried out after passing the review and approval of the State Food and Drug Administration (CFDA) and obtaining the clinical trial approval document. After the clinical trial is completed, the production can be applied, after passing the review and approval of CFDA and obtaining the drug production approval, can be produced and marketed.
Up to now, the accumulated research and development investment and other related expenditures of DPT project of Jianfeng Pharmaceutical Co., Ltd. are about 33 million yuan. The impact of
4. on listed companies and risk tips
DPT clinical application filed by the company has been accepted and will not have a significant impact on the company's recent operating results. After the clinical application of
is accepted, the clinical research work can only be carried out after passing the review and approval of CFDA and obtaining the clinical trial approval document. The results and time of the inspection, review and approval during the period are uncertain. Due to the long cycle and high risk of new drug research and development, the company will timely fulfill the obligation of information disclosure according to the progress of research and development. Please pay attention to the investment risk.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
August 25, 2016
More information
The company's vocational skill level independently identifies two new occupations
A few days ago, after the examination and approval of the Jinhua Municipal Bureau of Human Resources and Social Security, and reported to the Provincial Department of Human Resources and Social Security for examination and filing, Jianfeng Group's independent identification level of vocational skills was based on last year. Two new occupations (types of work) are chemical inspectors and organic synthesis workers.
2022
05-20
On May 12, Cai Xiaochun, deputy secretary of the Party group of Zhejiang Federation of industry and commerce, and his party visited Jianfeng group for investigation, visited Jinxi factory area of Jianfeng pharmaceutical factory and Jinxi internationalization project site, and had a discussion with Jiang Xiaomeng, chairman of the group company, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company.
2022
05-20
On the afternoon of April 6, Jiang Xiaomeng, chairman of the group company, was invited to participate in the Jinhua News Client Financial Media Interview column "Night Talk of the Two Sessions", as a representative of the Jinhua Municipal People's Congress, to talk about suggestions for the future development of Jinhua enterprises. As the chairman of the Jinhua City Federation of Industry and Commerce, Jiang Xiaomeng has a personal experience of various problems encountered in the development of Jinhua enterprises. After careful investigation and full preparation, he put forward two proposals on strengthening the empowerment and allocation of production factors and further enhancing the market competitiveness of enterprises in our city and further promoting the compliance construction of private enterprises in our city and reducing the risk of enterprise operation. In the "two sessions night talk" interview, he put forward his own views on these two topics.
2022
04-12
Group Companies Commend 2021 Advanced
On the morning of January 26, the group company held the 2021 annual summary commendation meeting to review the work of the previous year, make arrangements for the work of 2022, sign the 2022 economic responsibility system with various professional companies and directly affiliated enterprises, and solemnly commend the 2021 advanced collectives and individuals.
2022
02-08
Group Company Convenes Workers' Representative and Trade Union Member Representative Conference
The group company held a representative meeting of staff representatives and trade union members, elected members of the eighth trade union committee and members of various special committees, and Shi Fu was elected chairman of the eighth trade union of the group trade union.
2022
02-08
The group company held an annual safety and environmental protection work conference to comprehensively summarize and review the safety and environmental protection work in 2021, make arrangements for the safety and environmental protection work in 2022, and sign the safety and environmental protection work responsibility system.
2022
02-08
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page